Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

BACKGROUND: Mantle cell lymphoma (MCL) is an uncommon type of non-Hodgkin lymphoma with poor overall prognosis, requiring the development of new therapies. Lenalidomide is an immunomodulatory agent demonstrating antitumor and antiproliferative effects in MCL. We report results from a long-term subse...

Descripción completa

Detalles Bibliográficos
Autores principales: Zinzani, P. L., Vose, J. M., Czuczman, M. S., Reeder, C. B., Haioun, C., Polikoff, J., Tilly, H., Zhang, L., Prandi, K., Li, J., Witzig, T. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811905/
https://www.ncbi.nlm.nih.gov/pubmed/24030098
http://dx.doi.org/10.1093/annonc/mdt366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811905/
https://www.ncbi.nlm.nih.gov/pubmed/24030098
http://dx.doi.org/10.1093/annonc/mdt366

Ejemplares similares